Fig. 1
From: Identification of GRIN2D as a novel therapeutic target in pancreatic ductal adenocarcinoma
GRIN2D was identified as an oncogene in PDAC. (A). Workflow of in-vivo genome-wide RNAi screening. (B). GRIN2D was upregulated in PDAC cells, as compared to non-tumor HPDE cells. (C). IHC staining of GRIN2D in blood vessels and ducts with the respective markers PECAM-1 and CK19. GRIN2D was upregulated in PDAC tumor tissues, compared to adjacent non- tumor tissues. (D). GRIN2D expression was increased in PDAC tumors, as compared to normal, from two independent samples cohort GSE16515 and GSE15471. Data are from at least three independent experiments. Mean ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001